Blog

 

Avraham Raises $4M for MCI Trial

Avraham Pharmaceuticals Ltd.  has closed an investment round of approximately $4.0 million. Investors in the round include Yissum Research Development Company Ltd., the technology transfer arm of the Hebrew University of Jerusalem, Pontifax, Clal Biotechnology Industries, Integra Holdings, Yissum’s biotech holdings company, the Technion Research and Development Foundation Ltd. (TRDF)...
Read more

BioBlast Study for OPMD

BioBlast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced positive results from its HOPEMD Phase 2 six-month open-label clinical study in patients with oculopharyngeal muscular dystrophy (OPMD), a rare progressive muscle-wasting disease characterized by swallowing difficulties (dysphagia), leading to the risk of aspiration of food into the lungs,...
Read more

Breast Milk Mimic Improves Brain Function

Enzymotec announced that InCogTM, an innovative lipid composition that is intended to mimic certain characteristics of human breast milk contributing to cognitive development, demonstrated enhanced brain development and improved survival in a preclinical study. The study evaluated the effects of InCogTM in a term and preterm piglet model relevant for...
Read more

Can-Fite Phase III Arthritis

Can-Fite has submitted to the European Medicines Agency (EMA) a protocol design for its Phase III trial and Registration Plan for the Company’s lead compound CF101 in the treatment of rheumatoid arthritis following a pre-submission meeting with the EMA. The global trial is expected to commence in either the second...
Read more

Intensix Teams With Mayo Clinic

Israeli big data and intensive care analytics startup Intensix has signed an agreement with Mayo Clinic in the US to commence a study of early predictions of life-threatening complications in a critical care setting. The study will focus on the feasibility of using the Intensix platform to predict patient deterioration...
Read more